Gilead’s Raised 2026 Outlook Affirms HIV/PrEP Thesis, but GAAP Loss and Oncology Catalysts Loom

What happened

Gilead’s Q2 earnings call highlighted a raised 2026 base-business outlook, driven by sustained HIV treatment momentum and better-than-expected PrEP uptake from Yeztugo, aligning with the thesis’s expectation of ~$1B annual sales. This operational beat reinforces the core HIV cash-flow durability that underpins the investment case, even as management reiterates a full-year GAAP net loss due to $11.5B in acquired IPR&D charges. Trodelvy growth and the upcoming launches of BIC/LEN (PDUFA Aug 27, 2026) and anito-cel (Dec 23, 2026) add nearer-term catalysts, though oncology remains unproven and carries binary risk. The raised outlook reduces the probability of the bear-case scenario where Yeztugo stalls below $700M, but it does not eliminate the key risks of utilization conversion and payer friction highlighted in the master report. At $124, the stock still trades at a modest 16.8x earnings, but the thesis requires investors to look through accounting noise and trust that HIV/PrEP execution will be sustained until oncology delivers.

Implication

Gilead’s strengthened HIV/PrEP outlook supports the base-case valuation of $135 and reduces downside risk, making the stock’s risk/reward more attractive near current levels. However, the 2026 net loss from acquisition charges will likely continue to weigh on sentiment, and investors must be comfortable with the binary nature of the BIC/LEN and anito-cel decisions. PrEP utilization metrics and the containment of deal-related charges remain critical checkpoints; any misstep could quickly erode confidence. The market may view the raised guidance as a positive signal, but it will take a clean FDA approval and sustained Yeztugo demand to unlock the bull case of $155. For now, the thesis is incrementally stronger, but the full payoff still hinges on execution through year-end.

Thesis delta

The Q2 call materially de-risks the Yeztugo ramp and base HIV business, moving the thesis from 'potential buy' toward a higher-conviction stance. While the GAAP loss overhang persists, the raised outlook tilts the probability toward the base and bull cases, making entry near $124 more compelling for investors willing to tolerate near-term accounting noise.